Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
19
Active, not recruiting, industry sponsors, Rare and genetic disease, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed111
19 trials
Showing 1 to 19, recently updated first.
- Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)Active, not recruiting
Prevail TherapeuticsIndustry
NCT04411654 · 7 participants · Start Jun 29, 2021 · Primary completion Feb 2027
Drug: Methylprednisolone; Sirolimus and 1 more · For: Gaucher Disease, Type 2
Sites: Oakland, California; Minneapolis, Minnesota; New York, New York · 6 sites in all
- A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C DiseaseActive, not recruiting
Azafaros B.V.Industry
NCT07399704 · 21 participants (planned) · Start Feb 4, 2026 · Primary completion Jun 30, 2027
Drug: AZ-3102 · For: GM2 Gangliosidosis; Niemann-Pick Type C Disease
Sites: Água Verde, Brazil; Porto Alegre, Brazil; Rio de Janeiro, Brazil
- Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)Active, not recruiting
Prevail TherapeuticsIndustry
NCT04127578 · 32 participants (planned) · Start Jan 3, 2020 · Primary completion Aug 31, 2031
Drug: LY3884961; Methylprednisolone and 1 more · For: Parkinson Disease
Sites: Scottsdale, Arizona; Murrieta, California; Englewood, Colorado · 15 sites in all
- An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIBActive, not recruiting
JCR Pharmaceuticals Co., Ltd.Industry
NCT06488924 · 10 participants (planned) · Start Nov 5, 2024 · Primary completion Apr 30, 2030
Drug: JR-446 · For: Mucopolysaccharidosis III-B
Sites: Hiroshima, Japan; Okinawa, Japan; Tokyo, Japan · 4 sites in all
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type IIPivotal-lookingActive, not recruiting
AO GENERIUMIndustry
NCT05208281 · 32 participants (planned) · Start Nov 30, 2021 · Primary completion Dec 20, 2027
Drug: GNR-055 1.0-2.0-3.0 mg/kg; GNR-055 2.0 mg/kg and 1 more · For: Mucopolysaccharidosis Type II; Metabolic Diseases
Sites: Moscow, Russia; Saint Petersburg, Russia; Simferopol, Russia · 5 sites in all
- A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)Pivotal-lookingActive, not recruiting
Denali Therapeutics Inc.Industry
NCT05371613 · 65 participants · Start Jul 21, 2022 · Primary completion Dec 2027
Drug: tividenofusp alfa; idursulfase · For: Mucopolysaccharidosis II
Sites: Oakland, California; Chicago, Illinois; Hackensack, New Jersey · 30 sites in all
- An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis IIActive, not recruiting
JCR Pharmaceuticals Co., Ltd.Industry
NCT03708965 · 19 participants · Start Jan 1, 2019 · Primary completion Dec 31, 2026
Drug: JR-141 · For: Mucopolysaccharidosis II
Sites: Porto Alegre, Brazil; São Paulo, Brazil
- Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIAActive, not recruiting
JCR Pharmaceuticals Co., Ltd.Industry
NCT06095388 · 15 participants · Start Oct 4, 2023 · Primary completion Oct 31, 2029
Drug: JR-441; JR-441 and 1 more · For: Mucopolysaccharidosis III-A
Sites: Hamburg, Germany
- An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type IIPivotal-lookingActive, not recruiting
JCR Pharmaceuticals Co., Ltd.Industry
NCT04348136 · 27 participants · Start Sep 1, 2019 · Primary completion Mar 31, 2030
Drug: JR-141 · For: Mucopolysaccharidosis II
Sites: Fukui, Japan; Fukuoka, Japan; Gifu, Japan · 20 sites in all
- Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionActive, not recruiting
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02843035 · 12 participants · Start Jan 4, 2017 · Primary completion Oct 30, 2026
Drug: venglustat (GZ402671); imiglucerase · For: Gaucher Disease Type 1; Gaucher Disease Type 3
Sites: New Haven, Connecticut; Dallas, Texas; Fairfax, Virginia · 7 sites in all
- Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 GangliosidosisActive, not recruiting
Gemma BiotherapeuticsIndustry
NCT04713475 · 26 participants (planned) · Start Mar 17, 2021 · Primary completion Feb 2028
Drug: PBGM01 · For: GM1 Gangliosidosis; GM1 Gangliosidosis, Type I; GM1 Gangliosidosis, Type 2 and 1 more
Sites: Oakland, California; Minneapolis, Minnesota; New Brunswick, New Jersey · 7 sites in all
- Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)Pivotal-lookingActive, not recruiting
Napo Pharmaceuticals, Inc.Industry
NCT06721871 · 6 participants · Start May 1, 2025 · Primary completion Dec 2026
Drug: Crofelemer Powder for Oral Solution; Placebo Powder for Oral Solution · For: Microvillus Inclusion Disease; Congenital Disorders; Rare Diseases
Sites: Boston, Massachusetts; Rome, Italy; Dubai, United Arab Emirates
- A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase AlfaActive, not recruiting
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03019406 · 22 participants · Start Oct 12, 2017 · Primary completion Sep 30, 2019
Drug: Avalglucosidase alfa (GZ402666); Alglucosidase alfa (GZ419829) · For: Glycogen Storage Disease Type II-Pompe's Disease
Sites: Valhalla, New York; Durham, North Carolina; Seattle, Washington · 12 sites in all
- An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06254482 · 144 participants · Start Aug 25, 2023 · Primary completion Jul 16, 2029
Drug: Votoplam · For: Huntington Disease
Sites: Clayton, Australia; Westmead, Australia; Innsbruck, Austria · 24 sites in all
- Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive ImpairmentPivotal-lookingActive, not recruiting
TakedaTakeda (TAK)
NCT06031259 · 6 participants · Start Mar 5, 2024 · Primary completion Jan 1, 2029
Drug: Idursulfase-IT; Elaprase · For: Hunter Syndrome
Sites: Calgary, Canada; Vancouver, Canada; Toronto, Canada · 4 sites in all
- A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With PhenylketonuriaActive, not recruiting
SanofiSanofi (SNY)
NCT05972629 · 32 participants (planned) · Start Aug 7, 2023 · Primary completion Apr 2, 2030
Drug: SAR444836 · For: Phenylketonuria
Sites: San Francisco, California; Aurora, Colorado; Gainesville, Florida · 11 sites in all
- A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter SyndromeActive, not recruiting
Denali Therapeutics Inc.Industry
NCT04251026 · 47 participants · Start Jul 16, 2020 · Primary completion Feb 2031
Drug: tividenofusp alfa · For: Mucopolysaccharidosis II
Sites: Oakland, California; Chicago, Illinois; Chapel Hill, North Carolina · 7 sites in all
- AAV Gene Therapy Study for Subjects with PKUActive, not recruiting
BioMarin PharmaceuticalBioMarin (BMRN)
NCT04480567 · 100 participants (planned) · Start Sep 24, 2020 · Primary completion Dec 2027
Drug: BMN 307 · For: Phenylketonuria (PKU)
Sites: Tampa, Florida; Morristown, New Jersey; Birmingham, United Kingdom
- An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry DiseaseActive, not recruiting
4D Molecular TherapeuticsIndustry
NCT04519749 · 18 participants (planned) · Start Sep 1, 2020 · Primary completion Jan 2026
Drug: 4D-310 · For: Fabry Disease
Sites: La Jolla, California; Atlanta, Georgia; Pittsburgh, Pennsylvania · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.